World Delta COVID-19 variant doubles risk of hospitalization compared to Alpha strain, Scottish study finds
The Delta strain isn't the only COVID-19 variant you're likely to hear about. Here's a list
The World Health Organization has renamed the different strains of COVID-19 to take on the first four letters of the Greek alphabet.Under the changes, the four most concerning variants take on the first four letters of the Greek alphabet — Alpha, Beta, Gamma and Delta.
Ahas found the Delta variant carries double the risk of hospitalization compared to the Alpha strain, particularly in patients with five or more comorbidities. Scotland had determined that the Delta variant became the dominant strain in the country about a month ago.
Using the country’s COVID-19 surveillance program, researchers on behalf of Public Health Scotland analyzed data to investigate risk of hospital admission and estimate vaccinate effectiveness at preventing hospital admissions among likely Delta variant cases. The study was published Monday in
How the coronavirus Delta variant rampaged through India before spreading across the globe
As Delta rampaged through India undetected, doctors were confounded by the sheer scale of the virus's spread. This is how the COVID-19 variant fuelled a calamitous surge in cases before slipping beyond the country's borders.Daily confirmed infections were in the low hundreds and serological surveys, which detect COVID-19 antibodies in the blood, suggested more than half the city's population had been infected after overcoming three surges.
During the study period, which spanned from April 1 to June 6, 2021, there were 19,543 coronavirus cases, 377 of which required hospitalization. Of those hospitalizations, 134 cases were S gene-positive. In earlier analysis, researchers had determined that 97% of S genepositive cases sequenced in Scotland were the Delta variant, and 99% of Delta variants were S gene positive. S gene-negative cases were classified as Alpha variant infections.
Video: Delta COVID-19 variant detected in Melbourne (Reuters)
In the data, the researchers noted that S-gene positive cases occurred in all ages, but more so in younger children than compared to the Alpha variant. They also found that S gene-positive cases were associated with an increased risk of COVID-19 hospitalization admission when compared to S gene-negative cases, and that a greater number of relevant comorbidities increased the risk.
The Doctor Who Eliminated Smallpox Says COVID-19 Is Here to Stay
In some pockets of the United States, if you squint hard enough, the coronavirus pandemic might feel like it’s almost over. Larry Brilliant would beg to disagree. With U.S. COVID-19 deaths soon to surpass the domestic toll from the great influenza of a century ago even as widely available vaccines have worked wonders, Brilliant, the epidemiologist who worked with the WHO to help eradicate smallpox and was the science adviser for the eerily prescient film Contagion, thinks there’s still plenty left to worry about—but also lots of good news to appreciate.
Both the AstraZeneca COVID-19 vaccine and the Pfizer-BioNTech jab were shown to cut risk of infection and hospitalization due to the Delta variant, but protection against infection fell as compared with the Alpha variant.
However, the researchers noted that the analysis was observational in nature, and estimates of vaccine effectiveness "need to be interpreted with caution." They also said there were insufficient numbers on hospitalization admissions and the variants "to compare between vaccines in this respect."
"In summary, we show that the Delta VOC in Scotland was found mainly in younger, more affluent groups," the researchers wrote. "Risk of COVID-19 hospital admission was approximately doubled in those with the Delta VOC compared to the Alpha VOC, with risk of admission particularly increased in those with five or more relevant comorbidities."
Is India's Delta Plus a worrying Covid-19 variant? .
India says a new variant of the coronavirus is a 'variant of concern'. How worried should we be?A mutation is elevated from a "variant of interest" to a "variant of concern" (VOC) when it shows evidence of fulfilling at least one of several criteria, including easy transmission, more severe illness, reduced neutralisation by antibodies or reduced effectiveness of treatment and vaccines.